Biodesix Files 8-K on Financials
Ticker: BDSX · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1439725
| Field | Detail |
|---|---|
| Company | Biodesix Inc (BDSX) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, results-of-operations
Related Tickers: BDSX
TL;DR
Biodesix dropped an 8-K detailing its financial condition and results.
AI Summary
Biodesix, Inc. filed an 8-K on January 10, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhibits. The filing details the company's operational and financial status as of January 10, 2025.
Why It Matters
This filing provides investors with crucial updates on Biodesix, Inc.'s financial health and operational performance, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing with no immediate new risks or significant events disclosed.
Key Players & Entities
- BIODESIX INC (company) — Filer
- 0000950170-25-003717 (filing_id) — Accession Number
- January 10, 2025 (date) — Report Date
- Louisville, Colorado (location) — Principal Executive Office
FAQ
What specific financial results are being reported in this 8-K?
The filing indicates it covers 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but the specific details of these results are not provided in the provided text.
When was this 8-K report filed?
The report was filed on January 10, 2025.
What is the principal executive office address for Biodesix, Inc.?
The principal executive office is located at 919 West Dillon Rd, Louisville, Colorado 80027.
What is the SIC code for Biodesix, Inc.?
The Standard Industrial Classification (SIC) code for Biodesix, Inc. is 8071, which corresponds to Medical Laboratories.
Is this filing related to any specific event or is it a routine update?
The filing is an 8-K Current Report, typically used for significant events, but the provided text indicates it covers 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', suggesting it may include routine financial updates.
Filing Stats: 535 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-01-10 06:05:39
Key Financial Figures
- $0.001 — registered Common Stock, par value of $0.001 per share BDSX The Nasdaq Stock Mar
Filing Documents
- bdsx-20250110.htm (8-K) — 41KB
- bdsx-ex99_1.htm (EX-99.1) — 19KB
- img189760734_0.jpg (GRAPHIC) — 3KB
- 0000950170-25-003717.txt ( ) — 190KB
- bdsx-20250110.xsd (EX-101.SCH) — 31KB
- bdsx-20250110_htm.xml (XML) — 5KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On January 10, 2025, Biodesix, Inc. (the Company) issued a press release announcing certain preliminary and unaudited financial results of the Company for the fourth quarter and year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this Item 2.02 shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits: No. Exhibit 99.1 Press Release issued by Biodesix, Inc. dated January 10, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 10, 2025 BIODESIX, INC. By: /s/ Robin Harper Cowie Name: Robin Harper Cowie Title: Chief Financial Officer